Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid
Eli Lilly is licensing Sangamo Therapeutics’ AAV capsid for an undisclosed CNS disease target, and the $18 million upfront fee should give the beleaguered biotech a much-needed cash injection. The deal...
View ArticleArvinas touts healthy volunteer data for Parkinson's disease PROTAC
Arvinas reported early-stage data for its PROTAC program in healthy volunteers, hoping the results will eventually translate to patients with Parkinson’s disease. The data, which were shared Friday...
View ArticleNovo Nordisk adjusts its leadership team; Dyne alums migrate to Crescent...
→ Camilla Sylvest has moved on from Novo Nordisk after 28 years with the Danish pharma, including more than seven years as EVP of commercial strategy & corporate affairs. In response to her exit,...
View ArticleRelay Therapeutics does third round of layoffs in nine months, affecting...
Relay Therapeutics is downsizing for the third time since July. The Cambridge, MA-based biotech is letting go of about 70 employees, a spokesperson confirmed to Endpoints News on Friday morning. Relay had
View ArticleSarepta indicates it's safe to continue Elevidys dosing in Europe; Epsilogen...
Plus, news about Vickers Venture Partners: Sarepta Therapeutics says safety board clears paused Elevidys trials: An independent data monitoring committee concluded that three studies of the Duchenne ...
View ArticleRiboX Therapeutics quietly starts first circular RNA trial
A Shanghai-based startup quietly became the first in the world to start a clinical trial for a circular RNA therapy, a cutting-edge form of genetic medicine that could provide new ways to treat chronic...
View ArticleKennedy team defends Marks firing, while 20% of staff cuts may be 'mistakes'
At least 2,000 of the 10,000 HHS employees let go this week will be reinstated because of “mistakes,” Robert F. Kennedy Jr. said Thursday. One of his top deputies on Friday for the first time ...
View ArticleStates sue NIH over alleged grant cancellations, delays
Sixteen states on Friday sued the NIH over what they called “destructive efforts” to disrupt the agency’s grant process, in the latest legal challenge against the Trump administration’s efforts to...
View ArticleChina's retaliatory tariffs on US could mean more headwinds for drugmakers
China's announcement of 34% tariffs on all US imports — a retaliation against US tariffs that were announced this week — could create more challenges for drugmakers already navigating a dampened...
View ArticleFTC chairman seeks to revive PBM case
Federal Trade Commission Chairman Andrew Ferguson said he wants to bring back the agency’s case against pharmacy benefit managers, one day after the matter was put on hold because of the Trump...
View ArticleNovavax’s approval delay may signal warning for vaccine makers
On the precipice of FDA approval, Novavax's Covid vaccine is now in limbo while a decision to approve or reject it is held up. The delay reinforces a fear from other vaccine makers about how ...
View ArticleMarks was asked to provide non-existent vaccine risk data: WSJ
Ousted FDA biologics and vaccine chief Peter Marks was asked to provide non-existent data on the risk from measles vaccines, he told the Wall Street Journal in an interview describing the events...
View ArticleGSK and Pfizer resolve RSV vaccine patent fight
GSK and Pfizer have settled a lawsuit alleging Pfizer’s RSV shot Abrysvo infringed GSK’s patents. A Pfizer spokesperson told Endpoints News that as part of the settlement,“Pfizer has been granted a...
View ArticleTrump administration leaves obesity coverage expansion out of new Medicare rule
The Trump administration finalized new policies for some Medicare programs on Friday, but left out provisions that would have expanded coverage of anti-obesity drugs to millions of patients. Provisions...
View ArticleStaff cuts sweep across FDA; Tariff rollout raises questions; The R&D 15 is...
Welcome back to Endpoints Weekly! Much of this week’s headlines dealt with the fallout of cuts at the FDA and across HHS, notably including the ouster of CBER chief Peter Marks. Marks said he was ...
View ArticleQ&A: David Liu talks about science under pressure, teases “disease-agnostic”...
Gene editing pioneer David Liu was awarded one of three Breakthrough Prizes in Life Sciences for his invention of base and prime editing. The two CRISPR technologies, first published in 2016 and 2019,...
View ArticleGLP-1 weight loss discoverers win Breakthrough Prize: Q&A with Jens Juul Holst
Medicines based on glucagon-like peptide-1 (GLP-1) have revolutionized the treatment of diabetes and obesity. On Saturday, five scientists involved in the discovery and characterization of the peptide...
View ArticleGSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech
South Korean biotech ABL Bio has lined up another platform license agreement with a European pharma giant in the area of neurodegenerative diseases. ABL Bio has now garnered the interest of GSK, which...
View ArticleCell and gene therapy CDMO AmplifyBio shuts down over 'scarcity' of funding
Another CDMO has been hit by the slowdown of cell and gene therapy R&D. AmplifyBio closed its doors after struggling for months to find investor support and failing to find a buyer. “At the time ...
View ArticleRhythm touts Phase 3 win for rare obesity drug in people with brain damage
Rhythm Pharmaceuticals is looking to expand the potential market for its rare obesity treatment Imcivree beyond genetic disorders. The company said Monday the medicine reduced body weight in a...
View Article